Stem Cell Manufacturing Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global stem cell manufacturing market growth in terms of revenue was estimated to be worth $12.7 billion in 2023 and is poised to reach $21.8 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key factors driving the growth of the global stem cell manufacturing market are rising awareness about stem cell products in clinical applications and technical advancements in stem cell manufacturing. However, stringent regulatory policies are expected to restrain market growth to a certain extent.

Attractive Opportunities in the Stem Cell Manufacturing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Stem Cell Manufacturing Market Dynamics

DRIVER: Growing venture capital investment in stem cell research

Venture capital investment in stem cell research has been growing in recent years as investors see the potential for this field to revolutionize healthcare. Venture capital investment in stem cell research has experienced significant growth, reflecting the increasing recognition of its potential in revolutionizing healthcare and regenerative medicine. Stem cells possess the remarkable ability to differentiate into various cell types, making them a promising tool for treating a wide range of diseases and injuries. With the potential to address conditions such as neurodegenerative disorders, heart disease, and organ failure, the field of stem cell research has captured the attention of venture capitalists looking to support groundbreaking scientific advancements.

RESTRAINT: Significant operational costs associated with stem cell manufacturing and banking

Significant operational costs are associated with stem cell manufacturing and banking due to the complex and intricate processes involved. Firstly, the acquisition and maintenance of specialized laboratory equipment and facilities contribute to a substantial portion of the expenses. These facilities need to maintain strict standards for maintaining sterility, ensuring optimal growth conditions, and conducting quality control tests. Additionally, the costs of sourcing and maintaining a skilled workforce, including scientists, technicians, and quality assurance personnel, are considerable.

OPPORTUNITY: Government initiatives to boost the biotechnology and biopharmaceutical industries

Governments recognize the significant potential of the biotechnology and biopharmaceutical industries and have implemented various initiatives to foster their growth. These initiatives aim to promote research and development, attract investment, and accelerate the translation of scientific discoveries into innovative therapies and treatments. Governments provide funding through grants, tax incentives, and subsidies to support biotech and biopharma companies, especially startups and small enterprises.

CHALLENGE: Technical limitations associated with manufacturing scale-up

A major challenge in stem cell manufacturing is the requirement for large-scale expansion of stem cells while maintaining their unique characteristics and functionality. This necessitates the development of robust and standardized cell culture systems, which must be optimized to ensure consistent and reproducible outcomes on a larger scale. Additionally, the complex and delicate nature of stem cells demands stringent control over environmental factors such as temperature, pH, and oxygen levels throughout the manufacturing process. Achieving these conditions on a larger scale can be technically demanding and may require specialized equipment and infrastructure.

Stem Cell Manufacturing Market Ecosystem

Prominent companies in the market include well-established, financially stable manufacturers of stem cell manufacturing products. These companies have been operating in the market for several years and possess diversified, state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Becton, Dickinson, and Company (US), Eppendorf AG (Germany), Corning Inc. (US), Bio-Rad Laboratories (US),  Takara Bio Group (Japan), Fujifilm Holdings Corporation (Japan), Getinge AB (Sweden), Terumo Corporation (Japan), Bio-Techne Corporation (US), HiMedia Laboratories (India), StemCell Technologies, Inc. (Canada), Miltenyi Biotec GmBH (Germany), PromoCell (Germany), Anterogen Co. Ltd. (South Korea), CellGenix GmBH (India), Pluristem Therapeutics Inc. (Israel), Daiichi Sankyo (Japan), Organogenesis Holdings Inc. (US), Vericel Corporation (US), and American Cryostem Corporation (US).

The consumables segment accounted for the largest share of the product segment in the stem cell manufacturing industry in 2023.

Based on products, the stem cell manufacturing market is categorized into consumables, instruments, and stem cell lines. In 2023, the consumables segment accounted for the largest share of the stem cell manufacturing market. The major driver propelling the increasing demand for regenerative therapies, advancements in stem cell research, and increasing potential in treating various diseases, driving the need for efficient and reliable manufacturing processes.

The pharmaceutical & biotechnology companies segment dominated the end-user segment in the stem cell manufacturing industry in 2023.

Based on the end user, the segment of the stem cell manufacturing market is categorized into hospitals & surgical centers; pharmaceutical & biotechnology companies; cell & tissue banks; academic institutes, research laboratories, and CROs; and other end users. In 2023, the pharmaceutical & biotechnology companies segment dominated the end-user segment with the highest revenue share. The growing demand for regenerative medicine and increasing strategic collaborations to accelerate the development and commercialization of stem cell-based therapies.

North America was the largest market for stem cell manufacturing industry in 2023

Geographically, the stem cell manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. The stem cell manufacturing market is dominated by North America in 2023, and this dominance is anticipated to continue throughout the forecast period. The established research infrastructure, technological advancements, demand for precision medicine, supportive regulatory environment, robust biotechnology and healthcare industry, and availability of funding and investment drive the growth of the stem cell manufacturing market in North America. However, the high cost associated with research and products, which can limit the adoption of these products for some end users, especially smaller research institutions with limited budgets, are negatively impacting the market growth.

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the stem cell manufacturing market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland), Danaher Corporation (US), Sartorius AG (Germany), Becton, Dickinson, and Company (US), Eppendorf AG (Germany), Corning Inc. (US), Bio-Rad Laboratories (US),  Takara Bio Group (Japan), Fujifilm Holdings Corporation (Japan), Getinge AB (Sweden), Terumo Corporation (Japan), Bio-Techne Corporation (US), HiMedia Laboratories (India), StemCell Technologies, Inc. (Canada), Miltenyi Biotec GmBH (Germany), PromoCell (Germany), Anterogen Co. Ltd. (South Korea), CellGenix GmBH (India), Pluristem Therapeutics Inc. (Israel), Daiichi Sankyo (Japan), Organogenesis Holdings Inc. (US), Vericel Corporation (US), and American Cryostem Corporation (US).

Scope of the Stem Cell Manufacturing Industry

This report categorizes the stem cell manufacturing market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Consumables
  • Culture Media
  • Other Consumables
• Instruments
  • Bioreactors and Incubators
  • Cell Sorters
  • Other Instruments
• Stem Cell Lines
  • Hematopoietic stem cells (HSC)
  • Mesenchymal stem cells (MSC)
  • Induced Pluripotent Stem cells (iPSC)
  • Embryonic stem cells (ESC)
  • Neural Stem cells (NSC)
  • Multipotent adult progenitor stem cells

By Application

• Research Applications
  • Life science research
  • Drug discovery and development
• Clinical Application
  • Allogenic stem cell therapy
  • Autologous stem cell therapy
• Cell & Tissue Banking Applications

By End User

• Pharmaceutical & Biotechnology Companies
• Academic institutes, Research laboratories & contract research organizations
• Hospitals & surgical centers
• Cell & tissue banks
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • India
  • China
  • Rest of Asia Pacific (RoAPAC)
• Latin America
• Middle East Africa

Recent Developments of Stem Cell Manufacturing Industry

• In April 2023, U.S. Food and Drug Administration approved Omisirge (omidubicel), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. Developments like this are increasing the demand for stem cell therapies and culture media.
• In October 2022, Froilabo (France) announced the launch of a new range of fully automated lab-scale bioreactors. The bioreactor offers a great range of application possibilities suited to academia, research, process development and optimization, scale-up, and production.
• In January 2023, the life science group Sartorius extended a strategic collaboration partnership agreement with RoosterBio Inc. (RoosterBio) to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.
• In November 2021, GenScript announced today that it had launched the GenWand Double-Stranded DNA (dsDNA) Service for the manufacture of STEM CELL MANUFACTURING knock-in homology-directed repair (HDR) templates in T cell engineering.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst